Identifying new ways to target RAS proteins remains a priority in Oncology research. A Novartis team recently characterized a unique RAS protein “back-pocket” that may open new opportunities for drug discovery. Learn more in @natcomms.nature.com
www.nature.com/articles/s41...
Happy to share this landscape analysis from Novartis #GlobalHealth colleagues published in @natrevdrugdiscov.nature.com exploring 2 decades of data on approvals, clinical dev. trends, and modalities across 40 diseases with major GH implications.
www.nature.com/articles/d41...
Pleased to see this academic-industry collaboration lead to a new, AI-enabled view of MS disease progression that could potentially accelerate drug development and enhance the precision of clinical treatments for patients living with this disease. #AI www.nature.com/articles/s41...
Congratulations to the Novartis-led research team behind this @cp-cellchembiol.bsky.social paper. Their findings shed light on the context-specific nature of NEK7 inhibition of the NLRP3 #inflammasome via a novel molecular glue degrader. #TPD
Excited to see this work in @natchembio.nature.com from our Novartis teams. They report the discovery of a small molecule that binds pVHL, functioning as a molecular glue degrader. The findings suggest new opportunities to leverage VHL molecular glues.
www.nature.com/articles/s41...
#SciSky
Recent findings from our Oncology group in @nature.com point to potential new therapeutic possibilities for targeting RAS signalling. Fascinating work that advances understanding of this critical pathway. #SciSky #MedSky
www.nature.com/articles/s41...
Intriguing @nature.com perspective piece from @uoft.bsky.social and academic collaborators on the promise of multimodal models. Truly highlights the potential of recent breakthroughs in computational modeling to harness multi-omics datasets and accelerate discovery. www.nature.com/articles/s41...
Cell paper revealing a fascinating mechanism of HECT E3 ligase inhibition through an allosteric pocket - great combination of HTS and structure based design - shows the power of scientific collaboration. www.cell.com/cell/fulltex...
Congratulations to the authors of this paper investigating mGluR5 inhibition as a potential clinical approach in cocaine use disorder. Great science and important findings the research community can build on to further understand glutamate signaling in abuse disorders www.science.org/doi/10.1126/...
New insights on the mechanisms underlying GPCR specificity in this paper from Science Advances, with relevance to ligand design and drug development targeting GPCR subtypes. www.science.org/doi/10.1126/...
Well worth spending time studying this paper which highlights key role of microglia in Alzheimer’s disease.
I’m excited to share this excellent @natrevimmunol.bsky.social article from our Novartis Immunology team and colleagues on immune reset, its evolution and outlook in #therapeutics. Thank you to Richard Siegel and Tobias Junt for spearheading this important publication. www.nature.com/articles/s41...
Fascinating insight that AFib has a strong genetic component - opening up potential new therapeutic approaches. Congratulations to our own Steven Lubitz and all the other collaborators on this important paper. www.nature.com/articles/s41...
Excellent new review from David Gloriam shows why GPCRs continue to be of great interest for drug discovery. Therapies directed at 30 novel targets now in clinical trials.
Another UK Biobank data analysis investigates the impact of environmental and genetic factors on aging and age related diseases.
bsky.app/profile/mrcl... Excited to see a new spin out from @mrclmb.bsky.social
UK Biobank data continues to provide useful insight into difficult to treat diseases. Could these very early markers point to strategies for disease prevention?
